ArticleBlood cancer journal2025

Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis.

Akhil Rajendra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.